Form 4: IRADIMED Director Sells Shares Under 10b5-1 Plan

IRADIMED Director James B Hawkins sold 2,999 shares of common stock in multiple transactions on November 20, 2025, under a pre-arranged trading plan.

Summary

• James B Hawkins, a Director of IRADIMED CORP (IRMD), reported the sale of common stock.
• A total of 2,999 shares of common stock were disposed of in multiple transactions.
• All transactions occurred on November 20, 2025.
• The shares were sold at prices ranging from $88.20 to $88.50 per share.
• The sales were conducted pursuant to a Rule 10b5-1(c) pre-arranged trading plan.
• Following these transactions, James B Hawkins beneficially owns 30,545 shares of IRADIMED CORP common stock.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to insider selling, which typically signals a reduction in confidence. However, this is mitigated by the fact that the sales were executed under a pre-arranged 10b5-1 plan, suggesting the decision was not based on immediate, new negative information.

Positives

• The sales were executed under a Rule 10b5-1 plan, indicating they were pre-scheduled and not necessarily based on new, immediate negative information about the company.

Negatives

• A director selling shares, even under a pre-arranged plan, can sometimes be interpreted by the market as a reduction in insider confidence or a move to diversify holdings, potentially signaling a less bullish outlook.
• The total number of shares sold, 2,999, represents a reduction in the director's direct beneficial ownership.

Risks

• Insider selling, even if pre-planned, can sometimes lead to negative market sentiment or increased scrutiny from investors regarding the company's future prospects.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This insider transaction report does not provide information directly related to broader industry trends or competitive landscape. It solely details a director's personal stock trading activity.

Stakeholder Impact

• Shareholders may view the director's sale of shares as a potential signal of reduced confidence in the company's future prospects, although the 10b5-1 plan mitigates the immediate negative implications.

Key Dates

Recommendation

While a director's sale of shares can be a negative signal, the transaction was executed under a Rule 10b5-1 plan, indicating it was pre-scheduled and not necessarily based on new, immediate negative information. Investors should monitor future insider activity and company performance rather than reacting solely to this single event, which on its own does not warrant a strong buy or sell recommendation.

Keywords

IRADIMED, IRMD, Form 4, insider trading, stock sale, director, James B Hawkins, beneficial ownership, 10b5-1 plan